Cargando…
A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641994/ http://dx.doi.org/10.1186/1750-1172-10-S1-P8 |
| _version_ | 1782400281963659264 |
|---|---|
| author | Millns, Helen Bergemann, Rito Ackermann, Elizabeth Monia, Brett Lukas, Mary Ann |
| author_facet | Millns, Helen Bergemann, Rito Ackermann, Elizabeth Monia, Brett Lukas, Mary Ann |
| author_sort | Millns, Helen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4641994 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46419942015-11-19 A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy Millns, Helen Bergemann, Rito Ackermann, Elizabeth Monia, Brett Lukas, Mary Ann Orphanet J Rare Dis Poster Presentation BioMed Central 2015-11-02 /pmc/articles/PMC4641994/ http://dx.doi.org/10.1186/1750-1172-10-S1-P8 Text en Copyright © 2015 Millns et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Millns, Helen Bergemann, Rito Ackermann, Elizabeth Monia, Brett Lukas, Mary Ann A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy |
| title | A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy |
| title_full | A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy |
| title_fullStr | A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy |
| title_full_unstemmed | A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy |
| title_short | A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy |
| title_sort | phase 3 clinical trial with isis-ttrrx, a 2nd-generation antisense oligonucleotide targeting transthyretin (ttr), for the treatment of ttr amyloid cardiomyopathy |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641994/ http://dx.doi.org/10.1186/1750-1172-10-S1-P8 |
| work_keys_str_mv | AT millnshelen aphase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT bergemannrito aphase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT ackermannelizabeth aphase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT moniabrett aphase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT lukasmaryann aphase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT millnshelen phase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT bergemannrito phase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT ackermannelizabeth phase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT moniabrett phase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy AT lukasmaryann phase3clinicaltrialwithisisttrrxa2ndgenerationantisenseoligonucleotidetargetingtransthyretinttrforthetreatmentofttramyloidcardiomyopathy |